Merck (MRK, $78.58) Q1 earnings beat estimates, as Keytruda sales surge +55%
Merck first quarter earnings surpassed analysts’ estimates, thanks in large part to its success in lung cancer treatment.
For the three months ending in March, the pharma company’s GAAP earnings came in at $1.12 per share, beating the Street consensus estimates by seven cents. The earnings per share more than quadrupled from the year-ago quarter.
Merck’s total revenues surged +8% year-over-year to $10.8 billion, on the back of a +55% sales growth of Keytruda lung cancer treatment.
CEO Ken Frazier highlighted investments in research and development as one of the factors behind Merck’s strong quarter.
Looking ahead, Merck lifted its full-year 2019 revenue outlook to a range of $43.9 to $45.1 billion, while forecasting GAAP earnings to range between $4.02 and $4.12 per share.
The company also revealed a global restructuring plan - which includes closing plants and slashing jobs - that is expected to get completed by 2023. According to Merck, pre-tax charge of between $800 million and $12 billion will mostly go towards paying employee separation and plant closure costs.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MRK's RSI Oscillator recovers from overbought zone
The 10-day RSI Oscillator for MRK moved out of overbought territory on August 27, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 instances where the indicator moved out of the overbought zone. In 19 of the 35 cases the stock moved lower in the days that followed. This puts the odds of a move down at 54%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 40 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
The Moving Average Convergence Divergence Histogram (MACD) for MRK turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 24 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
MRK broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 53 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
Following a +2.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 200 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
The Aroon Indicator entered an Uptrend today. In 165 of 260 cases where MRK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.643) is normal, around the industry mean (19.050). MRK's P/E Ratio (117.496) is considerably higher than the industry average of (34.258). Projected Growth (PEG Ratio) (2.683) is also within normal values, averaging (5.614). Dividend Yield (0.023) settles around the average of (0.025) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of human and animal health products
Industry PharmaceuticalsMajor
Advertisement